MEDXF News and Press, Medexus Pharmaceuticals Inc From 06/17/21

Start Time: 08:00 End Time: 08:41 Medexus Pharmaceuticals Inc. (MEDXF) Q4 2021 Earnings Conference Call June 17, 2021, 08:00 AM ET Company Participants Ken d’Entremont - CEO Roland Boivin - CFO Tina Byers - IR Conference Call Participants Andre Uddin - Research Capital Justin Keywood -...

Medexus Pharmaceuticals (MEDXF): FY Non-GAAP Net loss of C$7.6M; GAAP Net loss of C$28.3M.Revenue of C$79.7M (+43.6% Y/Y)Adjusted EBITDA increased to C$8.2 million for fiscal 2021 compared to C$4.4 million for fiscal 2020.Press Release For further details see: Medexus Pharmaceuticals re...

Transformative licensing agreement for treosulfan in the U.S. completed February 2, 2021 Cash and cash equivalents of $18.7 million and available liquidity of $24.8 million at March 31, 2021 Management to host conference call at 8:00 AM Eastern Time on June 17th, 2021 ...

TORONTO and CHICAGO and MONTREAL, June 15, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSXV:MDP) (OTCQX: MEDXF) announced today that it has received final approval for listing of the Company’s common shares (the ...

TORONTO, CHICAGO and MONTREAL, June 14, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it will be presenting at the Raymond James Human Health Inn...

TORONTO and CHICAGO and MONTREAL, June 11, 2021 (GLOBE NEWSWIRE) -- , June 11, 2021 - Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today announced that it plans to host a conference call...

TORONTO, CHICAGO and MONTREAL, June 10, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today announced that it has expanded its medical affairs team in preparation for the...

TORONTO and CHICAGO and MONTREAL, June 09, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it is initiating immediate availability of Triamcinolone...

Medexus Pharmaceuticals Inc. (TSXV: MDP) (OTCQX: MEDXF), is a leading innovative and rare disease company with a strong North American commercial platform. From a foundation of proven best in class products we are building a highly differentiated company with a portfolio of innovative and hi...

TORONTO and CHICAGO and MONTREAL, June 01, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) ( TSXV: MDP , OTCQX: MEDXF ), today announced that management will present at the LD Micro Invitation...